{
    "brief_title": "Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients",
    "phase": "",
    "drugs": "['Cyclophosphamide 50mg', 'Letrozole 2.5 mg']",
    "drugs_list": [
        "Cyclophosphamide 50mg",
        "Letrozole 2.5 mg"
    ],
    "diseases": "['Breast Neoplasms', 'Neoplasm Metastasis']",
    "diseases_list": [
        "Breast Neoplasms",
        "Neoplasm Metastasis"
    ],
    "enrollment": "200.0",
    "inclusion_criteria": "inclusion criteria: \n\n Histologically confirmed metastatic breast cancers patients with estrogen receptor positive and/or progesterone receptor positive; \n\n Elderly women (age \u2265 65years) \n\n Failure or relapse from standard chemotherapy or unfit for chemotherapy \n\n Measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST); \n\n Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; \n\n Adequate bone marrow, liver and renal function; \n\n Estimated life expectancy of at least 3 months. \n\n ",
    "exclusion_criteria": ": \n\n Serious or uncontrolled concurrent medical illness \n\n Uncontrolled primary and metastatic brain tumor \n\n History of second primary malignancies \n\n Having been enrolled in other clinical trials within a month",
    "brief_summary": "This is a randomized clinical trial to investigate the efficacy of letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.",
    "NCT_ID": "NCT02583828"
}